Improving Healthcare, Reducing Costs, Saving Lives
Dedicated to reducing drug non-adherence while lowering healthcare costs and advancing medical research
Dedicated to reducing drug non-adherence while lowering healthcare costs and advancing medical research
We developed CuraServe™ to help patients manage their medications and thereby improve their health outcomes and advance medical research. Curaizon™ is a Danish Company with offices throughout Europe.
According to a report published by the World Health Organization, only about 50% of people in developed countries take their medications properly.
Drug non-adherence accounts for over 50% of visits to a doctor, 40% of long term care admissions and more than 50% of hospital readmissions.
Worldwide drug non-adherence results in approximately $700 billion in additional healthcare costs and the cost of treating a patient with low adherence is twice that of patient with high adherence.
The cost of treating a patient with low adherence is twice that of patient with high adherence.
Curaizon™ is a Danish company that has developed CuraServe™, a solution to improve drug adherence and bring game-changing benefits to patients and healthcare providers. Our solution works with patients, their families and healthcare professionals to ensure that patients take their medications as prescribed through a series of outreach tools, supported by predictive modelling tools and behavioural analysis, to increase the rate of drug adherence.
Curaizon™ uses the most practical, economically viable and fastest means of communication in order to secure high levels of adherence to prescriptions, avoid preventable hospitalizations and gather valuable data.
Our CuraServe™ technology helps ensure that patients take their medicines as prescribed by their doctor. By doing this, we help patients live longer and healthier lives. We also reduce the healthcare costs that occur when patients fail to take their medications properly.
Our CuraServe™ solution is deployed by national health services around the world. Our end users are the health service's patients who take any form of medication. We also work with academia, pharmaceutical and biotech industries, as well as other users of data via our CuraData™ platform.
Curaizon targets the 4.3 Billion patients around the world who suffer from long-term and chronic disease.
The global cost of non-adherence is over $700 billion each year and results in hundreds of thousands of lives lost prematurely. Adherence for chronic and long-term illness is less than 50%.